These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31306152)

  • 1. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
    Dikmen M; Gökhaner G; Cantürk Z
    Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
    Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
    Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprepitant Promotes Caspase-Dependent Apoptotic Cell Death and G2/M Arrest through PI3K/Akt/NF-
    Javid H; Afshari AR; Zahedi Avval F; Asadi J; Hashemy SI
    Biomed Res Int; 2021; 2021():8808214. PubMed ID: 34926694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
    Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
    Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
    Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
    J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
    Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C
    Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological evaluation of carbohydrate-based aprepitant analogs for neuroblastoma treatment.
    Valdivia V; Recio R; Lerena P; Pozo E; Serrano R; Calero R; Pintado C; Leal MP; Moreno-Rodríguez N; Organero JÁ; Khiar N; Fernández I
    Eur J Med Chem; 2024 Jan; 264():116021. PubMed ID: 38086194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
    Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
    Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors.
    Halik PK; Lipiński PFJ; Matalińska J; Koźmiński P; Misicka A; Gniazdowska E
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
    Matalińska J; Świć A; Lipiński P; Misicka A
    Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
    Muñoz M; Rosso M
    Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.
    Schoffelen R; Lankheet AG; van Herpen CML; van der Hoeven JJM; Desar IME; Kramers C
    Neth J Med; 2018 Apr; 76(3):109-114. PubMed ID: 29667586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
    Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
    Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
    Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
    Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGFβ regulates NK1R-Tr to affect the proliferation and apoptosis of breast cancer cells.
    Wang L; Wang N; Zhang R; Dong D; Liu R; Zhang L; Ji W; Yu M; Zhang F; Niu R; Zhou Y
    Life Sci; 2020 Sep; 256():117674. PubMed ID: 32380077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
    Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
    J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
    Muñoz M; Coveñas R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.